Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.

Authors: La Rosa C,Longmate J,Lacey SF,Kaltcheva T,Sharan R,Marsano D,Kwon P,Drake J,Williams B,Denison S,Broyer S,Couture L,Nakamura R,Kelsey MI,Krieg AM,Diamond DJ,Zaia JA,
Address: Division of Translational Vaccine Research, Beckman Research Institute of the City of Hope, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Journal: J Infect Dis.

Publication: 2012 Apr 15;205(8):1294-304. doi: 10.1093/infdis/jis107. Epub 2012 Mar 7.

abstract

BACKGROUND:

It has been reported that cytomegalovirus (CMV) pp65-specific T cells can protect hematopoietic cell transplant (HCT) recipients from CMV complications. Two candidate CMV peptide vaccines composed of the HLA A*0201 pp65(495-503) cytotoxic CD8(+) T-cell epitope fused to 2 different universal T-helper epitopes (either the synthetic Pan DR epitope [PADRE] or a natural tetanus sequence) were Clinically evaluated for safety and ability to elicit pp65 T cells in HLA A*0201 healthy volunteers.

METHODS:

Escalating doses (0.5, 2.5, 10 mg) of PADRE or Tetanus pp65(495-503) vaccines with (30 adults) or without (28 adults) PF03512676 adjuvant were administered by subcutaneous injection every 3 weeks for a total of 4 injections.

RESULTS:

No serious adverse events were reported, although vaccines used in combination with PF03512676 had enhanced reactogenicity. Ex vivo responses were detected by flow cytometry exclusively in volunteers who received the vaccine coadministered with PF03512676. In addition, using a sensitive in vitro stimulation system, vaccine-elicited pp65(495-503) T cells were expanded in 30% of volunteers injected solely with the CMV peptides and in all tested subjects receiving the vaccines coinjected with PF03512676.

CONCLUSIONS:

Acceptable safety profiles and vaccine-driven expansion of pp65(495-503) T cells in healthy adults support further evaluation of CMV peptide vaccines combined with PF03512676 in the HCT setting.

CLINICAL TRIALS REGISTRATION:

NCT00722839.

Related Articles
Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice.
Blood. 2002
Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice.
La Rosa C, Wang Z, Brewer JC, Lacey SF, Villacres MC, Sharan R, Krishnan R, Crooks M, Markel S, Maas R, et al. Blood. 2002 Nov 15; 100(10):3681-9. Epub 2002 Jul 12.
Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12.
Vaccine. 2006
Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12.
Jacobson MA, Sinclair E, Bredt B, Agrillo L, Black D, Epling CL, Carvidi A, Ho T, Bains R, Girling V, et al. Vaccine. 2006 Jun 19; 24(25):5311-9. Epub 2006 May 2.
Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients.
J Clin Virol. 2006
Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients.
Jacobson MA, Sinclair E, Bredt B, Agrillo L, Black D, Epling CL, Carvidi A, Ho T, Bains R, Adler SP. J Clin Virol. 2006 Mar; 35(3):332-7. Epub 2006 Jan 18.
Review Development of a cytomegalovirus vaccine: lessons from recent clinical trials.
Expert Opin Biol Ther. 2001
Review Development of a cytomegalovirus vaccine: lessons from recent clinical trials.
Gonczol E, Plotkin S. Expert Opin Biol Ther. 2001 May; 1(3):401-12.
Review Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant.
J Clin Virol. 2009
Review Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant.
Pass RF. J Clin Virol. 2009 Dec; 46 Suppl 4:S73-6. Epub 2009 Jul 31.
The immune response to human CMV.
Future Virol. 2012
The immune response to human CMV.
La Rosa C, Diamond DJ. Future Virol. 2012 Mar 1; 7(3):279-293.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.